Study of 300 million lab tests finds menopause triggers abrupt body-wide changes

Overview

Updated 1 hour ago

Menopause has long been treated as a slow, gradual shutdown of reproduction. A new analysis of 300 million laboratory tests from more than a million women in the United States and Israel argues the reality is sharper: a sudden, body-wide step change at the final menstrual period.

Researchers at the Weizmann Institute of Science used a deconvolution algorithm borrowed from astronomy, the same math used to sharpen blurry telescope images, to align test results by time from menopause rather than by age. Of 90 lab markers, 52 jumped abruptly at the final period, spanning bone, liver, kidney, lipid, and blood systems, not just sex hormones. Men of the same age showed no such step.

The finding reopens a timing question central to menopause medicine. If the body changes in a cliff rather than a slope, screening and hormone-therapy decisions made in the late menopause years may come too late.

Why it matters

If menopause is a physiological cliff, current screening and hormone-therapy timing may be years too late to prevent bone and metabolic damage.

Questions about this story

Free account needed to ask — your question is kept and asked for you right after sign-up. Answers are public.

No questions yet — be the first to ask.

Key Indicators

300 million

Laboratory tests analyzed

Routine lab results spanning the US-NHANES and Israel-Clalit cohorts, 1999 to 2024.

52 of 90

Tests with abrupt jump at menopause in women

Jump sizes ranged from 0.1 to 1.4 standard deviations across endocrine, bone, hepatic, lipid, and blood systems.

1 million+

Women studied

Cross-sectional data from two independent population-scale cohorts.

0.89

Correlation of jump sizes between the two datasets

Israel-Clalit and US-NHANES produced strongly matching results despite different populations and study designs.

Voices

Curated perspectives — historical figures and your fellow readers.

Ever wondered what historical figures would say about today's headlines?

People Involved

Uri Alon

Professor at Weizmann Institute of Science, lead author of the study

Leading the research team; preparing a randomized trial of pre-menopause hormone therapy

González (first name not reported)

Spanish gynecologist quoted in EL PAÍS coverage

Commenting on the study's clinical implications

Organizations Involved

Weizmann Institute of Science

Research University

Host institution for the study's lead author

Israeli research institute where Professor Uri Alon's group developed the deconvolution method and led the analysis.

Nature Medicine

Peer-reviewed medical journal

Published the peer-reviewed study

Monthly medical journal that published the menopause deconvolution study in October 2026.

Timeline

November 2025 October 2026

2 events Latest: Yesterday

October 2026
Study published in Nature Medicine
Latest Publication

The peer-reviewed paper appears, reporting abrupt jumps in 52 of 90 lab markers at the final menstrual period, with media coverage and expert commentary following.
Yesterday
November 2025
Preprint posted on arXiv
Research Release

The deconvolution analysis of 300 million lab tests circulates as an unreviewed preprint under the title about a systemic physiological cliff at menopause.
November 2025

Scenarios

Guidelines shift menopause screening earlier

Possible Resolves by End of 2028

Discussed by: Professor Uri Alon; ABC News; EL PAÍS coverage

If the cliff finding holds, professional bodies could move baseline bone-density screening into the late 30s or 40s and reconsider when menopausal hormone therapy should begin. Alon said checking bone density at 40 or 45, then considering hormone therapy as prevention, would follow from the data.

Randomized trial of pre-menopause hormone therapy launches

Likely Resolves by End of 2028

Discussed by: Professor Uri Alon, whose laboratory says it is preparing such a trial

Alon stated his lab is preparing a randomized trial of hormone therapy begun before the final menstrual period, measuring effects on bone and brain health. A registered trial would move the observational finding toward causal evidence and test whether early MHT prevents the cliff rather than repairing damage after it.

Findings contested by independent reanalysis

Possible Resolves by End of 2028

Discussed by: Australian experts via Scimex; gynecologist González in EL PAÍS

Critics note the study is retrospective and observational, relying on self-reported menopause information and population averages that may not describe individual women. An independent cohort analysis or a reanalysis using different assumptions could challenge the cliff interpretation or narrow which tests truly jump.

Historical Context

2 moments from history that rhyme with this story — and how they unfolded.

1996 to present

Study of Women's Health Across the Nation (1996)

The U.S. longitudinal SWAN study followed thousands of women through the menopause transition, establishing much of the current framework for how hormones change across perimenopause. It tracked follicle-stimulating hormone, estradiol, and other markers with repeated measurements over decades.

Then

SWAN became the reference standard for describing the menopause transition and its timing in individual women.

Now

Its findings underpin current screening and treatment windows for perimenopausal women.

Why this matters now

The new study, using cross-sectional population data, estimates key hormone shifts begin about seven years earlier than SWAN described — anti-Müllerian hormone falling roughly 15 years before the final period, estradiol about 12 years, and FSH rising about 14 years prior.

1990s to 2002

Women's Health Initiative hormone therapy trial (2002)

The U.S. Women's Health Initiative randomized trial halted its combined estrogen-progestin arm early after finding increased risks of breast cancer and cardiovascular events. The findings dramatically cut hormone therapy use worldwide and reshaped the risk calculus for treating menopause symptoms.

Then

MHT prescriptions fell sharply and prescribing guidance became far more cautious.

Now

Two decades later, MHT remains underused relative to symptom burden, and debates over timing and risk persist.

Why this matters now

The new study reports that women taking hormone therapy showed smaller jumps in 39 of 80 tests, reconnecting the cliff finding to the long-standing MHT risk-benefit debate and the question of when treatment should start.